326 related articles for article (PubMed ID: 17139643)
1. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
Maksymowych WP; Richardson R; Mallon C; van der Heijde D; Boonen A
Arthritis Rheum; 2007 Feb; 57(1):133-9. PubMed ID: 17266072
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state.
Tubach F; Ravaud P; Baron G; Falissard B; Logeart I; Bellamy N; Bombardier C; Felson D; Hochberg M; van der Heijde D; Dougados M
Ann Rheum Dis; 2005 Jan; 64(1):34-7. PubMed ID: 15130902
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and stability of the Patient Acceptable Symptom State (PASS) over time in patients with ankylosing spondylitis.
Wariaghli G; Allali F; Idrissi Z; Berrada K; Hmamouchi I; Abouqal R; Hajjaj-Hassouni N
Clin Exp Rheumatol; 2012; 30(1):106-9. PubMed ID: 22260741
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
6. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
7. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study.
Pavy S; Brophy S; Calin A
J Rheumatol; 2005 Jan; 32(1):80-5. PubMed ID: 15630730
[TBL] [Abstract][Full Text] [Related]
8. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
[TBL] [Abstract][Full Text] [Related]
9. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.
Calin A; Nakache JP; Gueguen A; Zeidler H; Mielants H; Dougados M
J Rheumatol; 1999 Apr; 26(4):975-9. PubMed ID: 10229431
[TBL] [Abstract][Full Text] [Related]
10. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.
Spoorenberg A; van Tubergen A; Landewé R; Dougados M; van der Linden S; Mielants H; van de Tempel H; van der Heijde D
Rheumatology (Oxford); 2005 Jun; 44(6):789-95. PubMed ID: 15757962
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):961-5. PubMed ID: 10229428
[TBL] [Abstract][Full Text] [Related]
13. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
Calin A; Garrett S; Whitelock H; Kennedy LG; O'Hea J; Mallorie P; Jenkinson T
J Rheumatol; 1994 Dec; 21(12):2281-5. PubMed ID: 7699629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
[TBL] [Abstract][Full Text] [Related]
15. Assessment of fatigue in the management of patients with ankylosing spondylitis.
Dernis-Labous E; Messow M; Dougados M
Rheumatology (Oxford); 2003 Dec; 42(12):1523-8. PubMed ID: 13130145
[TBL] [Abstract][Full Text] [Related]
16. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Kvamme MK; Kristiansen IS; Lie E; Kvien TK
J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
Song IH; Rudwaleit M; Listing J; Sieper J
Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
[TBL] [Abstract][Full Text] [Related]
18. Comparative responsiveness of 3 functional indices in ankylosing spondylitis.
Ruof J; Sangha O; Stucki G
J Rheumatol; 1999 Sep; 26(9):1959-63. PubMed ID: 10493677
[TBL] [Abstract][Full Text] [Related]
19. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
[TBL] [Abstract][Full Text] [Related]
20. [The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis].
Grazio S; Grubisić F; Nemcić T; Matijević V; Skala H
Reumatizam; 2009; 56(2):63-76. PubMed ID: 20429263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
